Jennifer L. Good - Mar 21, 2025 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role: President & CEO, Director
Signature: /s/ Christopher Galletta, attorney-in-fact
Stock symbol: TRVI
Transactions as of: Mar 21, 2025
Transactions value $: -$27,099
Form type: 4
Date filed: 3/25/2025, 04:30 PM
Previous filing: Mar 12, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRVI	Common Stock	Options Exercise	$7.53K	+5.26K	+2.47%	$1.43	219K	Mar 21, 2025	Direct
transaction	TRVI	Common Stock	Sale	-$34.6K	-5.26K	-2.41%	$6.58	213K	Mar 21, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRVI	Stock Option (right to buy)	Options Exercise	$0	-5.26K	-100%	$0.00	0	Mar 21, 2025	Common Stock	5.26K	$1.43	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.55 to $6.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2	This option was granted on May 15, 2015. The 5,263 shares of common stock underlying the option vested as to 25% of the shares on May 15, 2016 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through May 15, 2019.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.55 to $6.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

This option was granted on May 15, 2015. The 5,263 shares of common stock underlying the option vested as to 25% of the shares on May 15, 2016 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through May 15, 2019.